Current progress in dengue vaccines

Shu Wen Wan, Chiou Feng Lin, Shu-Ying Wang, Yu-Hung Chen, Trai-Ming Yeh, Hsiao-Sheng Liu, Robert Anderson, Yee-Shin Lin

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

Original languageEnglish
Article number37
JournalJournal of biomedical science
Volume20
Issue number1
DOIs
Publication statusPublished - 2013 Jun 17

Fingerprint

Dengue Vaccines
Viruses
Severe Dengue
Attenuated Vaccines
Dengue
Vaccines
Dengue Virus
Virus Diseases
Inactivated Vaccines
Subunit Vaccines
DNA Vaccines
Autoimmunity
Thrombocytopenia
Blood Vessels
Animal Models
Clinical Trials
Hemorrhage
Safety
Animals
Antibodies

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Wan, Shu Wen ; Lin, Chiou Feng ; Wang, Shu-Ying ; Chen, Yu-Hung ; Yeh, Trai-Ming ; Liu, Hsiao-Sheng ; Anderson, Robert ; Lin, Yee-Shin. / Current progress in dengue vaccines. In: Journal of biomedical science. 2013 ; Vol. 20, No. 1.
@article{67cb4dbd93a840189c8fd166a9c07067,
title = "Current progress in dengue vaccines",
abstract = "Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.",
author = "Wan, {Shu Wen} and Lin, {Chiou Feng} and Shu-Ying Wang and Yu-Hung Chen and Trai-Ming Yeh and Hsiao-Sheng Liu and Robert Anderson and Yee-Shin Lin",
year = "2013",
month = "6",
day = "17",
doi = "10.1186/1423-0127-20-37",
language = "English",
volume = "20",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

Current progress in dengue vaccines. / Wan, Shu Wen; Lin, Chiou Feng; Wang, Shu-Ying; Chen, Yu-Hung; Yeh, Trai-Ming; Liu, Hsiao-Sheng; Anderson, Robert; Lin, Yee-Shin.

In: Journal of biomedical science, Vol. 20, No. 1, 37, 17.06.2013.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current progress in dengue vaccines

AU - Wan, Shu Wen

AU - Lin, Chiou Feng

AU - Wang, Shu-Ying

AU - Chen, Yu-Hung

AU - Yeh, Trai-Ming

AU - Liu, Hsiao-Sheng

AU - Anderson, Robert

AU - Lin, Yee-Shin

PY - 2013/6/17

Y1 - 2013/6/17

N2 - Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

AB - Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

UR - http://www.scopus.com/inward/record.url?scp=84878818110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878818110&partnerID=8YFLogxK

U2 - 10.1186/1423-0127-20-37

DO - 10.1186/1423-0127-20-37

M3 - Review article

C2 - 23758699

AN - SCOPUS:84878818110

VL - 20

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 37

ER -